XML 15 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
Costs and Expenses:        
Research and development $ 2,944,652 $ 3,186,781 $ 10,392,004 $ 10,994,712
General and administrative 1,963,527 1,465,939 5,415,552 4,016,503
Loss from Operations (4,908,179) (4,652,720) (15,807,556) (15,011,215)
Change in fair value of derivative financial instruments-warrants and contingent consideration (2,710,447) 735,227 (3,041,457) 3,218,846
Loss before income taxes (7,618,626) (3,917,493) (18,849,013) (11,792,369)
Income tax benefit     1,908,003  
Net loss $ (7,618,626) $ (3,917,493) $ (16,941,010) $ (11,792,369)
Weighted Average Common Shares Outstanding        
Basic and Diluted (in shares) 63,301,676 27,297,311 53,688,464 25,403,001
Net Loss per Common Share        
Basic and Diluted (in dollars per share) $ (0.12) $ (0.14) $ (0.32) $ (0.46)